Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Change in Cash (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Change in Cash data on record, last reported at $312.0 million in Q4 2025.

  • For Q4 2025, Change in Cash rose 22.11% year-over-year to $312.0 million; the TTM value through Dec 2025 reached $203.0 million, up 9.72%, while the annual FY2025 figure was $203.0 million, 9.72% up from the prior year.
  • Change in Cash reached $312.0 million in Q4 2025 per PTCT's latest filing, up from -$346.8 million in the prior quarter.
  • Across five years, Change in Cash topped out at $700.5 million in Q1 2025 and bottomed at -$462.8 million in Q2 2025.
  • Average Change in Cash over 5 years is $39.1 million, with a median of -$4.6 million recorded in 2021.
  • Peak YoY movement for Change in Cash: skyrocketed 175514.0% in 2022, then crashed 545.34% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$100000.0 in 2021, then surged by 175514.0% to $175.4 million in 2022, then skyrocketed by 144.49% to $428.9 million in 2023, then tumbled by 40.42% to $255.5 million in 2024, then grew by 22.11% to $312.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $312.0 million in Q4 2025, -$346.8 million in Q3 2025, and -$462.8 million in Q2 2025.